Amarin Corporation plc announced the appointment of John F. Thero as the Company's Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and administrative matters of the Company and be actively involved in corporate development and other strategic and operational matters. He will report directly to Dr. Declan Doogan, Amarin's interim Chief Executive Officer. Mr. Thero has more than 20 years of senior financial and operational management experience including over 15 years supporting the growth of life science companies. Previously, Mr. Thero was Chief Financial Officer at ViaCell Inc., where he helped guide the company to its successful sale, and Abiomed Inc., during its transition from a development-stage company into a commercial entity. Mr. Thero began his professional career at Arthur Andersen LLP, during which time he became a Certified Public Accountant.

Amarin Corporation plc announced that the company's chief financial officer Alan Cooke will step down in the latest management upheaval at the firm. Mr. Cooke, president, chief operating officer and chief financial officer of the drug development business, is leaving the company business following its decision to transfer certain corporate functions from Amarin's Dublin office to the US. However, the firm said it would continue to operate an office in Dublin. Mr. Lynch assumed the post of chief executive in late 2007 following the departure of Rick Stewart in the wake of a clinical trial failure that dramatically undermined the business. He will continue as company chairman, a position he has held since he joined the Amarin board in 2000. He has been replaced by Amarin's head of research and development Dr. Declan Doogan, who assumes the position of interim chief executive.

Amarin Corporation plc announced changes to its board and management team, in conjunction with its separately announced $70 million private placement. Following the closing of the financing, Mr. Thomas Lynch, Chairman and Chief Executive Officer of Amarin, has decided he will step down as CEO and will continue as Chairman. Dr. Declan Doogan, Amarin's Head of Research and Development, has agreed to assume the role of Interim CEO. The financing was led by existing investor, Fountain Healthcare Partners on behalf of funds affiliated with other existing investors Sofinnova Ventures, Orbimed Advisors and Longitude Capital. The new investor group was led by funds affiliated with Abingworth LLP and included APG Asset Management, Great Point Partners, Tavistock Life Sciences Company and RA Capital. Dr. Manus Rogan of Fountain Healthcare Partners and Dr. Joseph Anderson of Abingworth LLP will join Amarin's board of directors. Manus Rogan, PhD, is a Co-founder and Managing Partner at Fountain Healthcare Partners. Joseph Anderson, PhD, is a Partner at Abingworth LLP. He has more than 20 years experience as a Fund Manager and Analyst in the pharmaceutical and bioscience sectors. Dr. Anderson is currently a Director of Algeta ASA.